Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    


Concert Genetics Releases Comprehensive Genetic Test ID System


 
Rob Metcalf, CEO

Concert Genetics has released its comprehensive genetic test identification system for use in the market, enabling a level of automation in test ordering, coverage, payment and clinical decision support that wasn't previously possible,

Concert's Genetic Testing Units (GTUs) are the first and only system that uniquely identifies all 160,000 genetic testing products, organizes them into a multi-level taxonomy, and incorporates new tests as they enter the market, which is currently happening at a rate of more than 30 per day. Initially developed as an internal test tracking system, Concert's GTUs have powered the company's widely used, end-to-end genetic test management solutions, becoming essential infrastructure for precision medicine in the process. Now they are available to the market at a time when the need for reliable test identification is critical for accuracy and reimbursement.

Ambiguity in test identification has created burdens for healthcare stakeholders. The company cited disagreements between health plans and laboratories about test reimbursement arising from the codes used to bill the test. Genetic tests are billed using an average of 6.9 codes per claim. in one study Concert found panel tests for hereditary cancer were billed with more than 2,100 different code combinations during a 36-month period. The inevitable confusion has led to a protracted series of denials and appeals that take away time and money.

"At Concert, we believe in the promise of precision medicine, and we recognize this promise will not become a reality until unnecessary friction is eliminated," said Rob Metcalf, CEO of Concert Genetics. "Today, every system of record in healthcare, from electronic medical records and lab information systems to billing and claims payment systems, operates with a different or incomplete language to identify tests. Without a common language, automated digital communication has been impossible, and manual work has been the only option. As of today, that is no longer the case."

Concert's GTU system assigns a five-digit alphanumeric code to each specific, orderable test from a specific lab. The system links to Concert's master test catalog and covers a wide range of clinical areas, including prenatal, pediatric, rare disease, pharmacogenomic, hereditary cancer, and somatic oncology tests. The system is organized into Concert's multi-level taxonomy, which groups the 160,000 individual testing products into almost 45,000 categories, which roll up into 34 domains and 8 clinical areas.

In the context of Concert's data platform, the test identification system also ties with other key data assets, including billing codes, lab quality information, and health plan medical coverage policies, enabling automation where manual work is otherwise required. This system builds on Concert's recently announced patent US10,896,405, for capabilities that support real-time, automated coverage determination and accurate reimbursement of genetic tests.

"The reason this system is transformative is that it eliminates manual work and potential for error at every step in the value chain," said Metcalf. "A test can be selected, authorized, ordered, resulted, billed, adjudicated, and correctly paid through a seamless exchange of information between systems that requires few if any manual stops, all because of unanimous agreement about the test in question."

From the homepage (ConcertGenetics.com), click on "Customer Login" and create a free account to access and view Concert GTUs, which are available on a royalty-free basis under the terms and conditions for many uses. Licenses for additional uses, including derivative works, can be obtained from Concert.

WEB:

Concert Genetics

Whitepaper on GTU System Design

 
Share:

Related Articles:


Recent Articles

Doctors Seeing Increase in Young Females with Tics, Verbal Outbursts Similar to Tourette syndrome

An international phenomenon of involuntary movements and vocalizations in adolescent girls, similar to the tics seen in Tourette syndrome, is now believed to be a functional movement disorder.

Read More

KraftCPAs healthcare cybersecurity webinar October 28

Read More

Acadia CEO to Retire

The Board of Directors of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) announced that Debbie Osteen will retire as CEO. Ms. Osteen will continue to serve on Acadia's Board of Directors and will assist in the selection and transition of the new CEO.

Read More

NEW FINDINGS FROM PRESS GANEY REVEAL MILLENNIAL NURSES ARE MOST LIKELY TO QUIT, AND NEARLY 30% OF NURSES ARE AT RISK OF LEAVING THEIR ORGANIZATION

Flight Risk Analysis of 100,000 U.S.-based healthcare workers underscores the importance of addressing the nurse staffing crisis

Read More

Research on Using Fluid Biomarkers to Advance Drug Treatments and Therapies for Alzheimer's, Traumatic Brain Injury, Concussion, and Other Neurodegene

New developments in the field of blood biomarkers for brain diseases including traumatic brain injury (TBI), and neurodegenerative diseases such as Alzheimer's, were unveiled during three lectures at the 25th Biennial World Congress of Neurology, October 3-7, 2021, and available virtually through the WCN 2021 portal.

Read More

Ataga Leading $3 Million AI Study For Predicting Kidney Function Decline in Sickle Cell Patients

Kenneth Ataga, MD, Director of the Center for Sickle Cell Disease at the University of Tennessee Health Science Center (UTHSC), was recently awarded $3.2 million from the National Heart, Lung and Blood Institute for a project that enlists artificial intelligence in the fight against sickle cell disease.

Read More

Research Team Awarded $3 Million to Study Weight Loss, Bone Frailty Link in Diabetics

Two researchers in the Department of Preventive Medicine at the University of Tennessee Health Science Center have received a $3 million award from the National Institute on Aging to study why bones become more frail and prone to fracture in diabetics who achieve long-term weight loss.

Read More

AMA Publishes New Study Monitoring Competition in U.S. Health Insurance Markets

Twentieth edition of AMA study shows continued lack of competition

Read More

Grant Creates Center for Maternal, Pediatric Precision Therapeutics

Vanderbilt University Medical Center has been awarded a five-year, $6 million grant from the National Institutes of Health (NIH) to serve as a center of excellence for Maternal and Pediatric Precision in Therapeutics (MPRINT).

Read More

Change in Respiratory Care Strategies for Preterm Infants Improves Health Outcomes

A decade's worth of data shows that neonatologists are shifting the type of respiratory support they utilize for preterm infants, a move that could lead to improved health outcomes.

Read More

Email Print
 
 

 

 


Tags:
Concert Genetics, Concert GTUs, Genetic Testing, Lab Reimbursement, Precision Medicine, Revenue Cycle Management
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: